Navigation Links
Sanofi-aventis Announces Non-Binding Offer to Acquire Genzyme
Date:8/29/2010

oncology and vaccines research units in Cambridge.  Genzyme would become the global center for excellence for Sanofi-Aventis in rare diseases and further increase Sanofi-Aventis'  presence in the greater Boston area.
  • Continuation of Genzyme's Legacy within Sanofi-Aventis: Genzyme's rare disease business would be managed as a stand-alone division under the Genzyme brand, with its own R&D, manufacturing and commercial infrastructure, similar to how Sanofi-Aventis has handled other recent transactions.  Genzyme's management and employees would play a key role within Sanofi-Aventis following the acquisition.

  • Fully Financed, All-Cash Premium Offer: The purchase price would be paid in cash, offering immediate, substantial and certain value for Genzyme's shareholders.  Our offer is fully financed and is not subject to a financing contingency.

  • As I indicated in my July 29 letter to you, in addition to these compelling reasons, we believe there are many others that demonstrate why Sanofi-Aventis is the right partner for Genzyme.  Sanofi-Aventis has significant expertise executing and integrating acquisitions, and a strong track record of creating value through those acquisitions by enhancing their performance through leveraging Sanofi-Aventis' capabilities.  Sanofi-Aventis has demonstrated that it is a good corporate partner by enabling its affiliates to maintain their distinctive culture and focus on their core strengths.  Sanofi-Aventis is strong financially with a market capitalization of approximately $75 billion, annual revenue of approximately $38 billion and annual EBITDA of approximately $16 billion.  From Sanofi-Aventis' perspective, the proposed transaction would provide a new sustainable growth platform.

    It is our preference to work together with you and the Genzyme Board to reach a mutually agreeable transaction.   As we have consistently stated, we place
    '/>"/>

    SOURCE Sanofi-aventis
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Sanofi-Aventis and Novalar File Marketing Authorization Application for OraVerse® in Five Key European Countries
    2. Oramed Pharmaceuticals and sanofi-aventis Enter Into an Agreement for the Insulin Supply of Orameds Oral Insulin Capsules
    3. Sanofi-aventis Successfully Completes The Acquisition of Chattem, Inc.
    4. Sanofi-aventis Successfully Completes Tender Offer for Chattem, Inc.
    5. Sanofi-aventis Obtains Antitrust Clearance in Connection With Chattem, Inc. Tender Offer
    6. Sanofi-aventis Commences Tender Offer for All Outstanding Shares of Chattem, Inc.
    7. Sanofi-aventis to Acquire Chattem Inc., Creating a Strong U.S. Consumer Healthcare Platform
    8. Intelliject, Inc. Enters Into Licensing Agreement with sanofi-aventis for U.S./Canada Rights to Novel Epinephrine Auto-injector
    9. Sanofi-aventis U.S. and Intelliject, Inc. Sign Licensing Agreement for Novel Epinephrine Auto Injector in North America
    10. Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial Fibrillation
    11. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/21/2014)... Calif. , Nov. 20, 2014  Edwards Lifesciences ... in the science of heart valves and hemodynamic monitoring, ... giving in 2014 to support a strong launch of ... Matters , and to improve the global communities where ... 2014, Edwards, global corporate giving will exceed $8 million, ...
    (Date:11/21/2014)... , Nov. 20, 2014 /CNW Telbec/ - KLOX Technologies ... the following appointments: Todd Martensen ... the newly created role of Chief Commercial Officer, to ... using topical photoconverter gel for the treatment of chronic ... traumatic wounds, recently approved in Europe ...
    (Date:11/21/2014)... Fla. , Nov. 20, 2014   Coqui ... become the first U.S. commercial producer of Molybdenum-99 (Mo-99), ... contract with INVAP to design its Medical ... Mo-99 is the parent isotope of Technetium-99, ... procedures worldwide. In 2012, Congress passed legislation making it ...
    Breaking Medicine Technology:Edwards Lifesciences Increases Charitable Giving In 2014 To Support Launch Of Every Heartbeat Matters 2KLOX Technologies announces executive appointments 2KLOX Technologies announces executive appointments 3KLOX Technologies announces executive appointments 4Coqui RadioPharmaceuticals Inks Deal With INVAP 2
    ... 2010 United Seating & Mobility (USM) , one ... excited to announce today that it has finalized a transaction ... The transaction applies to Fridley, MN serving the greater ... and Appleton, WI; RehabTECH will continue to operate its Illinois ...
    ... Dec, 2, 2010 SRI International, an independent ... it is collaborating with PhenoMatriX (PMX), a biotechnology ... drugs such as cisplatin and related analogues are ... have served as major weapons against solid tumors ...
    Cached Medicine Technology:SRI International and PhenoMatriX Collaborate to Develop Platin-Based Chemotherapies 2SRI International and PhenoMatriX Collaborate to Develop Platin-Based Chemotherapies 3SRI International and PhenoMatriX Collaborate to Develop Platin-Based Chemotherapies 4
    (Date:11/22/2014)... Greenville, Sc (PRWEB) November 23, 2014 ... officially opened its doors in the downtown Greenville area. ... of Downtown Greenville , decided to open her own ... such amazing results with the patients. , AlignLife ... the proper tools. With a focus on chiropractic care ...
    (Date:11/22/2014)... 2014 PrettyTailor , an outstanding ... new big promotion. Customers can buy new dresses at ... can visit its website. , As a matter of ... dresses. It mainly provides four types of wedding outfits, ... flower girl dresses. It also provides a variety of ...
    (Date:11/22/2014)... (PRWEB) November 23, 2014 A classic black ... of the most famous dress suppliers, has unveiled its new ... new dresses are now offered at a big discount, up ... special offer. , The new black prom dresses, made ... order to meet the needs of all customers, the company ...
    (Date:11/22/2014)... 2014 BambooFlooringChina.com is a famous ... proudly released its new collection of bamboo mats ; ... to 29% off. , According to the sales ... grass, making it a highly renewable resource. Their bamboo mats ... mixing color which comes from natural bamboo with caramel bamboo ...
    (Date:11/22/2014)... New York, NY (PRWEB) November 22, 2014 ... Australia’s Therapeutics Goods Administration (TGA) approved it for ... Glutathione was approved and listed within the Therapeutic ... http://www.comlaw.gov.au/Details/F2014L01277 , Kyowa Hakko’s Setria® Glutathione ... Chem, a biotech specialist that sources and imports ...
    Breaking Medicine News(10 mins):Health News:AlignLife of Downtown Greenville is Now Open and Accepting New Patients 2Health News:Customers Are Welcome to Shop at PrettyTailor.com 2Health News:New Black Prom Dresses from BellasDress.com 2Health News:Trendy Bamboo Mats Online Now By BambooFlooringChina.com 2Health News:Setria® Glutathione Now Available in Australia 2Health News:Setria® Glutathione Now Available in Australia 3
    ... Childhood cancer survivors diagnosed later with non-melanoma skin cancer ... tumor within 15 years, according to research led by ... percent of survivors in this Childhood Cancer Survivor Study ... skin cancer developed another more aggressive cancer within 15 ...
    ... June 2010 Elsevier, a world-leading healthcare and ... an agreement with Tarrytown, New York based InfoDesk ... for pharmaceutical and life science companies. The ... technological know-how paves the way for the development ...
    ... available in German . Early detection is ... every lump turns out to be a malignant tumor. To ... a biopsy and examine the removed tissue under the microscope. ... but also highly time consuming. Research scientists at the Fraunhofer ...
    ... 8, 2010) A University of Minnesota study definitively shows ... an increased life expectancy. The research is published in the ... The findings stem from the Program on Surgical Control ... at the University of Minnesota in 1975. Researchers evaluated 838 ...
    ... unique study with sunitinib suggest that it might be ... to treat HIV-positive cancer patients to achieve therapeutic benefit. ... treat their HIV, much more or considerably less chemotherapy ... NCI-supported AIDS Malignancy Consortium (AMC). The trial design ...
    ... 2010 The Institute for Research in Immunology and ... a new research funding model that brings together the ... accelerate the discovery of new anti-cancer therapeutics. Inspired by ... athletes at the Vancouver Winter Olympics, B2Discovery,s mission is ...
    Cached Medicine News:Health News:Non-melanoma skin cancer may help identify survivors at increased risk for future cancers 2Health News:Elsevier and InfoDesk collaborate to co-develop federated drug pipeline intelligence solution 2Health News:Detecting tumors faster 2Health News:Consortium seeks best treatment for HIV-positive cancer patients 2Health News:Consortium seeks best treatment for HIV-positive cancer patients 3Health News:B2Discovery: Entrepreneurs and researchers join forces to conquer cancer 2
    ... Activins are polypeptide hormones which belong ... superfamily. The TGF- superfamily is a ... which control many aspects of development, ... Other members incude TGF-s, bone morphogenetic ...
    ... also known as bone Gla protein, is ... is a major component of the noncollagenous ... osteoblasts in bone, with a small amount ... chondrocytes [1]. During bone formation, newly synthesized ...
    ... Insulin-like growth factor binding protein-2 (IGFBP-2) is ... have been proposed) which specifically bind and ... The binding affinity of IGFBP-2 for IGF-II ... for IGF-I [1], suggesting a role in ...
    ... suppress the secretion of FSH (follicle stimulating ... two distinct chains, or subunits (alpha and ... the alpha-subunit and betaA-subunit. Inhibin B consists ... dimeric forms of the molecule, containing both ...
    Medicine Products: